highly accelerated region 1BGenealiases: HAR1R · LINC00065 · NCRNA00065
Q-omics provides the consensus-scored HAR1B profile across patient tissues and cancer cell-line models. HAR1B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HAR1B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HAR1B RNA expression shows 12,284 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where HAR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HAR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HAR1B survival associations across molecular data types. HAR1B RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HAR1B RNA expression–survival associations across cancer types. High HAR1B expression shows unfavorable associations in KIRC, ACC, CHOL and COAD, but favorable associations in LGG and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HAR1B RNA expression.
This table summarizes HAR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HAR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HAR1B shows lower tumor expression in UCEC and THCA and higher tumor expression in KIRC, BRCA, HNSC and COAD. The KIRC box plot shows higher HAR1B RNA expression in tumor versus normal tissue (log2 FC = +0.184, t-test p < 0.001).
This table shows molecular features associated with HAR1B in patient tissues and cancer cell lines. In patient samples, HAR1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
